Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Lillian L. L. Leong"'
Autor:
Samuel D Vasikaran, Paul Sheehan, Juwaini Abu Bakar, Kirsten Hoad, Damon A. Bell, Lillian L. L. Leong
Publikováno v:
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 49:285-288
Background Prolactin has multiple forms and macroprolactin, which is thought not to be bioavailable, can cause a raised serum prolactin concentration. Gel filtration chromatography (GFC) is currently the gold standard method for separating macroprola
Autor:
Charlene J. Stephens, William Silvester, Roger R. Taylor, Lillian L. L. Leong, Ross M. Graham, Marian Sturm
Publikováno v:
Critical Care Medicine. 22:204-212
To study the plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis.A prospective, nonrandomized control study.Intensive care unit in a university hospital.Thirteen critically ill male patients with clinical se
Autor:
Charlene J. Stephens, Marian Sturm, Roger R. Taylor, Ross M. Graham, Om Prakash Yadava, Lillian L. L. Leong
Publikováno v:
Europe PubMed Central
Platelet activating factor (PAF) is a potent mediator in inflammatory responses and maybe involved in various disease states. Degradation of PAF in plasma results from the action of a specific, lipoprotein associated, acetylhydrolase. The aim was to
Publikováno v:
Clinical and Experimental Pharmacology and Physiology. 17:645-651
SUMMARY 1. Based largely upon in vitro studies, vitamin E has been reported to inhibit phospholipase A2 activity, to alter phospholipid metabolism and reduce platelet aggregation. 2. The effect of dietary supplementation with D-α-tocopherol (1500 iu
Publikováno v:
Journal of molecular and cellular cardiology. 24(6)
Myocardial ischemia is associated with accumulation of lyso-phospholipids, including lyso-platelet activating factor, the degradation product and precursor of platelet activating factor. These compounds produce cellular and microvascular damage and,
Publikováno v:
Cardiovascular research. 26(2)
Objective: Systemic administration of platelet activating factor (PAF, l- O -alkyl-2-acetyl- sn -glycero-phosphocholine) produces hypotension and decreased cardiac output; in isolated heart preparations PAF increases coronary vascular resistance and
Autor:
Marian Sturm, Charlene J. Stephens, William Silvester, Ross M. Graham, Roger R. Taylor, Lillian L. L. Leong
Publikováno v:
Journal of Molecular and Cellular Cardiology. 24:ix
Autor:
Geoffrey M. Clarke, Marian Sturm, Roger R. Taylor, Julie A. Strophair, Lillian L. L. Leong, Fabio M. Leonelli
Publikováno v:
Clinical Science. 77:561-566
1. Evidence suggests that activation of phospholipase A2 and production of eicosanoids and platelet-activating factor (PAF) are involved in various responses associated with severe tissue damage and shock. It was postulated that the plasma level of t
Publikováno v:
Journal of Molecular and Cellular Cardiology. 21:S114